<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lumasiran: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lumasiran: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lumasiran: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="130214" href="/d/html/130214.html" rel="external">see "Lumasiran: Drug information"</a> and <a class="drug drug_patient" data-topicid="130253" href="/d/html/130253.html" rel="external">see "Lumasiran: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55154018"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Oxlumo</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56857812"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Oxlumo</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55173266"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Hydroxyacid Oxidase 1 (HAO1)-Directed Small Interfering Ribonucleic Acid (siRNA)</span></li></ul></div>
<div class="block don drugH1Div" id="F55150518"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary hyperoxaluria type 1:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: SUBQ: 6 mg/kg/dose once monthly for 3 doses.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: SUBQ: 3 mg/kg/dose once monthly; begin 1 month after last loading dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing: Altered Kidney Function: Neonatal: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function: </b>SUBQ: There are no dosage adjustments for any degree of kidney impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis:</b> SUBQ: No dosage adjustment necessary; administer after hemodialysis if administered on dialysis days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing: Hepatic Impairment: Neonatal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin &gt;1 to 1.5 times ULN <b>or</b> AST &gt;ULN): SUBQ: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (total bilirubin &gt;1.5 to 3 times ULN with any AST): SUBQ: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (total bilirubin &gt;3 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dop drugH1Div" id="F55150519"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d611b7b1-21ef-4683-8869-1e300c0b0f03">Primary hyperoxaluria type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary hyperoxaluria type 1:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight &lt;10 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: SUBQ: 6 mg/kg/dose once monthly for 3 doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: SUBQ: 3 mg/kg/dose once monthly; begin 1 month after last loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight 10 to &lt;20 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: SUBQ: 6 mg/kg/dose once monthly for 3 doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: SUBQ: 6 mg/kg/dose every 3 months; begin 1 month after last loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≥20 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: SUBQ: 3 mg/kg/dose once monthly for 3 doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose: SUBQ: 3 mg/kg/dose every 3 months; begin 1 month after last loading dose.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55150520"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b>Infants, Children, and Adolescents: SUBQ: No dosage adjustment necessary for any degree of kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis:</b> Infants, Children, and Adolescents: SUBQ: No dosage adjustment necessary; administer after hemodialysis if administered on dialysis days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Infants, Children, and Adolescents: SUBQ: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F55150522"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: SUBQ:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin &gt;1 to 1.5 times ULN <b>or</b> AST &gt;ULN): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (total bilirubin &gt;1.5 to 3 times ULN with any AST): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (total bilirubin &gt;3 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F55170197"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="130214" href="/d/html/130214.html" rel="external">see "Lumasiran: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d611b7b1-21ef-4683-8869-1e300c0b0f03">Primary hyperoxaluria type 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary hyperoxaluria type 1: SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: 3 mg/kg/dose once monthly for 3 doses.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: 3 mg/kg/dose every 3 months, begin 1 month after last loading dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> If scheduled dose is delayed or missed, administer as soon as possible then resume monthly or quarterly dosing from the most recently administered dose.</p></div>
<div class="block dora drugH1Div" id="F55170199"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: No dosage adjustment necessary for any degree of kidney function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis, intermittent (thrice weekly): No dosage adjustment necessary; administer after hemodialysis if administered on dialysis days.</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F55170200"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (total bilirubin ≤ ULN and AST &gt; ULN; or total bilirubin ≤ 3× ULN): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (total bilirubin &gt;3 times the ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F55159803"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Injection site pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (including erythema at injection site, pain at the injection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Immunologic: Antibody development</p></div>
<div class="block coi drugH1Div" id="F55049478"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to lumasiran or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F55170185"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Anti-lumasiran antibodies: Anti-drug antibodies were identified in 6% of patients during clinical trials, although no clinically significant differences in the safety, pharmacokinetic, or pharmacodynamic profiles were observed in patients who tested positive for anti-lumasiran antibodies.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection site reactions: Injection site reactions, including erythema, pain, pruritus, and swelling, may occur; generally resolves within 1 day.</p></div>
<div class="block foc drugH1Div" id="F55154019"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxlumo: 94.5 mg/0.5 mL (0.5 mL)</p></div>
<div class="block geq drugH1Div" id="F55154017"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55195462"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Oxlumo Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">94.5 mg/0.5 mL (per 0.5 mL): $70,018.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56857813"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxlumo: 94.5 mg/0.5 mL (0.5 mL)</p></div>
<div class="block admp drugH1Div" id="F55150523"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: SUBQ: For SUBQ use only; should be administered by health care professional. Do not use if solution is discolored, cloudy, or contains particulate matter. Administer SUBQ into the abdomen (avoid area around the navel), thigh, or side or back of the upper arms; rotate injection site. Do not inject into scar tissue or areas that are red, inflamed, or swollen. Dose volumes &gt;1.5 mL should be equally divided into multiple syringes; each syringe should be administered at a separate site at least 2 cm apart. For dose volumes &lt;0.3 mL, use a 0.3 mL syringe; if using a 0.3 mL (30 unit) insulin syringe, each unit is 0.01 mL.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose</i>
<i>:</i> If scheduled dose is delayed or missed, administer as soon as possible, then resume monthly or quarterly dosing from the most recently administered dose.</p></div>
<div class="block adm drugH1Div" id="F55170201"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> For SUBQ administration by a health care professional only. Inject into the abdomen (avoid area around the navel), thigh, or side or back of upper arms; rotate injection sites. Avoid injecting into scar tissue or areas that are reddened, inflamed, or swollen. Divide injection volumes &gt;1.5 mL equally into multiple syringes; inject at least 2 cm apart. Discard unused portion.</p></div>
<div class="block sts drugH1Div" id="F55170187"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vial at 2°C to 25°C (36°F to 77°F) in original container.</p></div>
<div class="block usep drugH1Div" id="F55049788"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels (FDA approved in all ages).</p></div>
<div class="block mst drugH1Div" id="F55170180"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Lumasiran may be confused with Lumigan.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55194892"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55194889"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F55170183"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F55150524"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for injection-site reactions.</p></div>
<div class="block pha drugH1Div" id="F55170188"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Reduces the amount of available glyoxylate, a substrate for oxalate production, by targeting hydroxyacid oxidase 1 (HAO1) messenger RNA in hepatocytes through RNA interference, subsequently decreasing glycolate oxidase enzyme levels.</p></div>
<div class="block phk drugH1Div" id="F55170189"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: ≤2 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 4.9 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 85%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily by endo- and exonucleases to oligonucleotides of shorter lengths.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 4 hours (range: 0.5 to 12 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;26% as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522214"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Oxlumo</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Oxlumo (lumasiran) [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxlumo.1">
<a name="Oxlumo.1"></a>Oxlumo (lumasiran) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies Inc; May 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 130215 Version 31.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
